These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 11557115)

  • 21. p53 expression in oat and non-oat small cell lung carcinomas: correlations with proliferating cell nuclear antigen.
    Korkolopoulou P; Oates J; Crocker J; Edwards C
    J Clin Pathol; 1993 Dec; 46(12):1093-6. PubMed ID: 7904273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study.
    Graziano SL; Tatum A; Herndon JE; Box J; Memoli V; Green MR; Kern JA
    Lung Cancer; 2001; 33(2-3):115-23. PubMed ID: 11551406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thyroid transcription factor-1 (TTF-1) expression in human lung carcinomas: its prognostic implication and relationship with wxpressions of p53 and Ki-67 proteins.
    Myong NH
    J Korean Med Sci; 2003 Aug; 18(4):494-500. PubMed ID: 12923324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased expression of integrin beta1 is a poor prognostic factor in small-cell lung cancer.
    Oshita F; Kameda Y; Ikehara M; Tanaka G; Yamada K; Nomura I; Noda K; Shotsu A; Fujita A; Arai H; Ito H; Nakayama H; Mitsuda A
    Anticancer Res; 2002; 22(2B):1065-70. PubMed ID: 12168902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum p53 antibodies: predictors of survival in small-cell lung cancer?
    Murray PV; Soussi T; O'Brien ME; Smith IE; Brossault S; Norton A; Ashley S; Tavassoli M
    Br J Cancer; 2000 Dec; 83(11):1418-24. PubMed ID: 11076647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 expression in locally advanced pharyngeal squamous cell carcinoma.
    Lassaletta L; Brandáriz JA; Benito A; de la Cruz J; Gómez C; Ballestín C; Hitt R; Colomer R; Alvarez-Vicent JJ
    Arch Otolaryngol Head Neck Surg; 1999 Dec; 125(12):1356-9. PubMed ID: 10604414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical study of p53 in non-small cell lung cancer before and after preoperative chemotherapy.
    Korobowicz E; Zdunek M
    Pol J Pathol; 2000; 51(2):71-6. PubMed ID: 10974929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P53 immunostaining predicts chemosensitivity in non-small cell lung cancer: A preliminary report.
    Kawasaki M; Nakanishi Y; Yatsunami J; Takayama K; Ochiai S; Xinhai P; Kuwano K; Hara N
    Cancer J Sci Am; 1996; 2(4):217-20. PubMed ID: 9166535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased expression levels of p53 correlate with good response to cisplatin-based chemotherapy in non-small cell lung cancer.
    Oshita F; Nishio K; Kameda Y; Mitsuda A; Ikehara M; Tanaka G; Yamada K; Nomura I; Noda K; Arai H; Ito H; Nakayama H
    Oncol Rep; 2000; 7(6):1225-8. PubMed ID: 11032919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical detection of P53 protein is not associated with a poor prognosis in non-small-cell lung cancer.
    Passlick B; Izbicki JR; Häussinger K; Thetter O; Pantel K
    J Thorac Cardiovasc Surg; 1995 Jun; 109(6):1205-11. PubMed ID: 7776684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
    Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C
    Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome.
    Mishina T; Dosaka-Akita H; Kinoshita I; Hommura F; Morikawa T; Katoh H; Kawakami Y
    Br J Cancer; 1999 Jun; 80(8):1289-95. PubMed ID: 10376986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing.
    Cortazar P; Gazdar AF; Woods E; Russell E; Steinberg SM; Williams J; Ihde DC; Johnson BE
    Clin Cancer Res; 1997 May; 3(5):741-7. PubMed ID: 9815744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
    Lee YC; McCrystal MR; Christmas TI
    N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Semi-quantitative assessment of 99Tcm-sestamibi uptake in lung cancer: relationship with clinical response to chemotherapy.
    Ceriani L; Giovanella L; Bandera M; Beghe B; Ortelli M; Roncari G
    Nucl Med Commun; 1997 Nov; 18(11):1087-97. PubMed ID: 9423210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomas.
    Stefanaki K; Rontogiannis D; Vamvouka C; Bolioti S; Chaniotis V; Sotsiou F; Vlychou M; Delidis G; Kakolyris S; Georgoulias V; Kanavaros P
    Anticancer Res; 1998; 18(3A):1689-95. PubMed ID: 9673391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of p53 and glutathione S-transferase-pi relates to clinical drug resistance in non-small cell lung cancer.
    Nakanishi Y; Kawasaki M; Bai F; Takayama K; Pei XH; Takano K; Inoue K; Osaki S; Hara N; Kiyohara C
    Oncology; 1999 Nov; 57(4):318-23. PubMed ID: 10575319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer.
    Kawasaki M; Nakanishi Y; Kuwano K; Takayama K; Kiyohara C; Hara N
    Eur J Cancer; 1998 Aug; 34(9):1352-7. PubMed ID: 9849416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.